health pharma news today obesity drugs glp-1 Giants Bet on Next-Generation Treatments to Sustain Growth GLP-1 drugs transform obesity care,
Description
DPP-IV-Resistant, Long-Acting Oxyntomodulin Derivatives
doi: 10.1056/NEJMoa2032183 [DOI] [PubMed] [Google Scholar] 235
January to May 2026 (In Progress): Remaining TRIUMPH Phase 3 trials (1, 2, and 3) are being completed
Endocrine Reviews, 44 , 1432
While not approved specifically for weight loss, clinical trials showed average weight reduction of 3-5% of body weight, making it the least potent option in this category for weight management
For patients who cannot take stimulants unlike phentermine, Contrave is non-stimulant
